Converting theory into Practice Module X
Under the educational collaboration agreement pioneer in a business school our students will develop during our programmes projects and thesis based on real projects in collaboration with our educational partners. Over the years we have been working in the main therapeutics areas creating plans in oncology, central nervous system, rare disease, Dengue, among others.
Those projects are managed under confidentially and the objective is the interaction with the principal researcher, the technology transfer managers, and with the BBI coordinador and board of lectures in order to develop real plans to develop those drug candidates.
Partners & Jury
The Thesis of our management programmes is based on a scientific & business commercial plan developed with companies and based on real intellectual property projects from our partners in Europe. During the EMBA, the students work with leading managers for real a real success scenario proposal that will be subject to a tribunal of experts with a scientific, financial investment and industry background at the end of the year. Every year we count with a guest jury of experts from different nationalities to contribute to the evaluation and enrich the experience for the students and the companies with different cultural approaches.
Shaun Grady
Chair of AstraZeneca UK, Cambridge, United Kingdom
Andrea Burgos
Head of Alliance Management at NewAsmterdam Pharma, Amsterdam, The Netherlands
Robin Owen
Head of Alliance Management and Integration at AstraZecenca, Northamptonshire, United Kingdom
Christopher Church
Head of Technology Search, Evaluation and Transactions, BD&L, at AstraZeneca, Cambridge, UK
Caroline Austin
Vice President, Head of Transactions, Business Development at AstraZeneca, Cambridge, UK
Mindy Daeschner
Co-Founder at Norn Ventures, London, UK
Nicholas Draeger
Founder and Director at Cederberg GmbH, Basel area, Switzerland
Marie Chivers
Founder at Facilipharma, Great Hormead, United Kingdom
Internazionalisation
The learning objectives of our executive programmes is to acquire a deep understanding in the Life Sciences’ commercial ecosystem for developing innovation. In particular, the business interactions between academia, the biotechnology sector and the established pharmaceutical industry are analysed from a global perspective to understand how they deliver new treatments for patients.
Scientific Management
Our programmes are designed for professionals willing to experience a deep immersion into the sector and to develop new specialisations, which can help to further their professional development in the pharmaceutical industry and the biotechnology sector. The courses are ideal for students looking to expand their contacts into international networks in the Life Sciences industry and who are keen to develop their career into more senior management positions
Students first
Our course covers corporate finance, market access and healthcare economics, as well as preclinical and clinical regulatory requirements. Further modules cover medical technologies, technology transfer and entrepreneurship, organisational behaviour and developing an understanding of global strategies for new drug approvals, as well as the effective commercialisation of other related Life Sciences’ technologies
Alumni Network
The learning objectives of our executive programmes is to acquire a deep understanding in the Life Sciences’ commercial ecosystem for developing innovation. In particular, the business interactions between academia, the biotechnology sector and the established pharmaceutical industry are analysed from a global perspective to understand how they deliver new treatments for patients.
Global Network
The Biotechnology Business Institute’s programmes offer professional career development options, based on the most relevant areas of management to the Life Sciences industry. The different specialisations in the course provide an individual career perspective for each student, while working in groups provides an interactive perspective of working across the Life Sciences’ ecosystem.
Events
Our programmes are designed for professionals willing to experience a deep immersion into the sector and to develop new specialisations, which can help to further their professional development in the pharmaceutical industry and the biotechnology sector. The courses are ideal for students looking to expand their contacts into international networks in the Life Sciences industry and who are keen to develop their career into more senior management positions
Become part of the decision-making process of real case studies while you develop your international management skills
Our educational method combines the theoretical classes and a EMBA thesis to develop with our research center partners, technology transfers offices and biotechnology based companies. That allow to our EMBA candidates to understand the reality of the decision-making process to expand internationally new research lines, businesses and the development of new healthcare products, either due to licensing agreements or setting up the biotechnology-based company.
Every year depending on our candidates needs and their career development programme we select the best partnerships to develop the EMBA final project plan. These are some of the collaborations that we have created over the academic years.
These are some of the projects that the BBI candidates have develop over the years in collaboration with technology transfers officers, research centers and biotechnology based companies.
2025: AAVantgarde. Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease.
AAVantgarde's mission is to retain and rejuvenate sight for patients with inherited retinal disorders (IRDs) by next-generation therapies. Two lead programs in Ophthalmology with a high unmet need: Usher Syndrome Type 1B associated retinitis pigmentosa (Usher1B) and Stargardt disease.
2025: Neopharmed Gentili. The wellbeing and longevity of both individuals and families are at the center of what we do.
Neopharmed Gentili promotes innovative solutions aimed at supporting the entire family’s health and wellbeing across all age groups, from the children to the elderly. We specialize in bringing to market solutions of high therapeutic value, with the aim of helping people lead healthier and longer lives, as a result of our commitment across multiple therapeutic areas.
2024: Maxion therapeutics. We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets.
Using our revolutionary KnotBody® technology, we are creating first-in-class and best-in-class protein therapeutics for treating previously untreatable ion channel and GPCR-driven diseases. We are leveraging this technology to deliver safe, efficacious and long-acting drugs against previously undruggable targets.
2024: Cell Guidance Systems' mission is to develop products and services that enhance the human condition and protect our shared environment
We develop technologies that enable the delivery of bioactive molecules, controlling cell fate for medical, research, and biomanufacturing applications. From our base in Cambridge, England, we develop therapeutic products as well as medical research tools and technologies that expand the possibilities of life sciences and medicine.
2023: Carbometrics. Our core competency is the design, synthesis, and derivatisation of highly selective and robust synthetic Glucose Binding Molecules.
Our principal technology is the world’s most selective synthetic Glucose Binding Molecule (GBM) – a perfectly optimised 3D-scaffold matched to bind glucose. Specific molecular recognition is routine for biology, but has proved difficult to achieve in synthetic systems. Carbohydrate substrates are especially challenging, because of their diversity and similarity to water, the biological solvent.
2022: Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK.
Talisman Therapeutics is a neurodegenerative disease drug discovery company, based on the Babraham Research Campus in Cambridge UK. We are committed to transforming the discovery of treatments for neurodegenerative disease, with a focus in dementia. Talisman uses novel, proprietary human stem cell models of neurodegenerative disease.
2022: CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. CIC bioGUNE, member of the Basque Research and Technology Alliance (BRTA).
key research center within the national and international scientific landscape and has emerged as a knowledge source in the area of health science. The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry, Structural, Molecular and Cell Biology, with the aim of developing a more Precise Medicine for the future.
PROFESSIONAL DEVELOPMENT AS THE CORE OF OUR EDUCATIONAL MODEL
These are some of the projects that the BBI candidates have develop over the years in collaboration with technology transfers officers, research centers and biotechnology based companies.